Hebei Changshan Biochem Pharma Market Cap ($2.69 Billion)
Market Cap & Net Worth: Hebei Changshan Biochem Pharma (300255)
Hebei Changshan Biochem Pharma market cap. Hebei Changshan Biochem Pharma (SHE:300255) has a market capitalization of $2.69 Billion (CN¥18.36 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #5089 globally and #829 in its home market, demonstrating a 6.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hebei Changshan Biochem Pharma's stock price CN¥19.98 by its total outstanding shares 919060878 (919.06 Million). Also see Hebei Changshan Biochem Pharma cash flow conversion for how efficiently the company converts equity into cash flow.
Hebei Changshan Biochem Pharma Market Cap History (2015–2026)
Hebei Changshan Biochem Pharma market cap history from 2015 to 2026. Data shows growth from $1.28 Billion to $2.69 Billion (6.90% CAGR). Check 300255 live share price for real-time trading data and today's change.
Hebei Changshan Biochem Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hebei Changshan Biochem Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300255 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.61x
Hebei Changshan Biochem Pharma's market cap is 2.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.28 Billion | $915.99 Million | $156.30 Million | 1.40x | 8.20x |
| 2016 | $1.04 Billion | $1.12 Billion | $175.49 Million | 0.93x | 5.95x |
| 2017 | $838.35 Million | $1.42 Billion | $196.92 Million | 0.59x | 4.26x |
| 2018 | $543.84 Million | $1.65 Billion | $139.99 Million | 0.33x | 3.88x |
| 2019 | $726.27 Million | $2.07 Billion | $225.29 Million | 0.35x | 3.22x |
| 2020 | $826.79 Million | $2.36 Billion | $252.84 Million | 0.35x | 3.27x |
| 2021 | $1.09 Billion | $2.97 Billion | $233.57 Million | 0.37x | 4.66x |
| 2022 | $736.24 Million | $2.34 Billion | $17.51 Million | 0.32x | 42.04x |
| 2023 | $1.75 Billion | $1.41 Billion | -$1.24 Billion | 1.24x | N/A |
| 2024 | $2.69 Billion | $1.03 Billion | -$249.48 Million | 2.61x | N/A |
Competitor Companies of 300255 by Market Capitalization
Companies near Hebei Changshan Biochem Pharma in the global market cap rankings as of November 5, 2026. Also see Hebei Changshan Biochem Pharma total assets for a full breakdown of the balance sheet.
Key companies related to Hebei Changshan Biochem Pharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Hebei Changshan Biochem Pharma (2015–2026)
Market capitalization of Hebei Changshan Biochem Pharma from 2015 to today. Between 2015 and today, Hebei Changshan Biochem Pharma's market cap moved from $1.28 Billion to $ 2.69 Billion, with a yearly change of 6.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.69 Billion | -67.83% |
| 2025 | CN¥8.35 Billion | +210.66% |
| 2024 | CN¥2.69 Billion | +53.65% |
| 2023 | CN¥1.75 Billion | +137.65% |
| 2022 | CN¥736.24 Million | -32.31% |
| 2021 | CN¥1.09 Billion | +31.55% |
| 2020 | CN¥826.79 Million | +13.84% |
| 2019 | CN¥726.27 Million | +33.55% |
| 2018 | CN¥543.84 Million | -35.13% |
| 2017 | CN¥838.35 Million | -19.74% |
| 2016 | CN¥1.04 Billion | -18.52% |
| 2015 | CN¥1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hebei Changshan Biochem Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.69 Billion USD |
| MoneyControl | $2.69 Billion USD |
| MarketWatch | $2.69 Billion USD |
| marketcap.company | $2.69 Billion USD |
| Reuters | $2.69 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more